Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0
version of its patented DehydraTECH(TM) oral drug-delivery technology has
demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream
than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing the company
reads, “The company’s 2.0 technology is specifically being developed for
effectiveness in helping to deliver its drug payload across the blood-brain
barrier, a natural biological system of blood vessels and endothelial cells
that bar most drugs from accessing the brain’s central-nervous-system
hierarchy. The ability to effectively deliver drugs to the brain is of keen
interest to developers of drugs designed to beneficially target the central
nervous system. . . . Lexaria’s research and development showed that
DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue
than generic industry-control formulations and 487% more than the original
DehydraTECH technology, according to the company’s news release.”
To view the full article, visit http://ibn.fm/4HHq5
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
